Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,Physical Therapy, Sports Therapy and Rehabilitation,General Medicine,Radiation
Reference34 articles.
1. Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, JanssenAG WEC, Van Royen E. [123I] FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:133–40.
2. Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I] FP-CIT SPET in differentiating patients with presynaptic Parkinsonism from those with other forms of Parkinsonism. Eur J Nucl Med. 2001;28:266–72.
3. Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, Tatsch K. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson’s disease: implications for a preclinical diagnosis. Arch Neurol. 2000;57:205–8.
4. Benamer HT, Patterson J, Grosset DG, Booij J, De Bruin K, Van Royen E, Speelman JD, Horstink MHIM, Sips HJWA, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V. Accurate differentiation of Parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503–10.
5. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC. Iodine-123-N-omega-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson’s disease. J Nucl Med. 1998;39:1143–8.